Search "Farxiga patient assistance program" today and you'll find a wall of pages describing AZ&Me as if you can still sign up for free brand-name Farxiga. As of mid-2026, that's out of date for anyone applying for the first time — and publishing that information without the update risks sending someone down a dead-end application process.
Here's what actually happened, who it affects, and what a realistic plan looks like now depending on whether you're already enrolled, brand new to Farxiga, or somewhere in between.
Farxiga (dapagliflozin) treats type 2 diabetes, heart failure and chronic kidney disease, and its uninsured cash price has generally run in the $550–$780 range for a 30-day supply depending on pharmacy and region. That price is exactly why the assistance program mattered so much — and exactly why its closure to new patients is worth understanding in detail before you build a plan around it.
Table of Contents
- What Changed on May 1, 2026
- Are You Affected? Three Scenarios
- Farxiga Savings Card vs AZ&Me vs Generic: Comparison
- If You're Already Enrolled in AZ&Me
- If You're New to Farxiga in 2026
- Medicare and Medicaid Patients
- Decision Tree: What's Your Move?
- Step-by-Step: Switching to Generic Dapagliflozin
- What to Do If You're Denied or Priced Out
- Frequently Asked Questions
What Changed on May 1, 2026
AstraZeneca's AZ&Me Prescription Savings Program — the charitable arm that had provided free Farxiga to qualifying uninsured and underinsured patients — stopped taking new Farxiga and Xigduo XR applications on that date. AstraZeneca notified currently enrolled patients and their providers about the change the month before, in April 2026.
| Date | Event |
|---|---|
| April 2026 | AstraZeneca notifies enrolled patients and providers of the upcoming change |
| May 1, 2026 | AZ&Me stops accepting new Farxiga and Xigduo XR applicants |
| May 1 – Dec 31, 2026 | Already-enrolled patients continue receiving assistance |
| December 31, 2026 | AZ&Me support for Farxiga and Xigduo XR ends entirely |
Why this happened: AstraZeneca's stated reasoning is the arrival of generic dapagliflozin in broad supply during 2026. Manufacturer patient assistance programs generally exist to bridge the gap for brand-name drugs without an affordable generic — once that gap closes, the manufacturer typically winds the program down for that specific drug rather than keeping it open indefinitely.
Are You Affected? Three Scenarios
| Your Situation | What This Means for You |
|---|---|
| Enrolled in AZ&Me for Farxiga before May 1, 2026 | Assistance continues through December 31, 2026 — plan your next step before then |
| Newly prescribed Farxiga after May 1, 2026, uninsured or underinsured | AZ&Me is not an option — look at generic dapagliflozin or independent foundations instead |
| Commercially insured, any date | AZ&Me was never your program — the Farxiga Savings Card is the relevant tool, unaffected by this change |
Farxiga Savings Card vs AZ&Me vs Generic Dapagliflozin
These three options solve different problems, and only one of them — the savings card — is unaffected by the May 2026 closure.
| Feature | Farxiga Savings Card | AZ&Me (Farxiga) | Generic Dapagliflozin |
|---|---|---|---|
| Current status | Active, unaffected | Closed to new applicants since May 2026 | Available, growing pharmacy stock through 2026 |
| Who it's for | Commercially insured or cash-paying patients | Previously: uninsured/underinsured, income-qualifying | Anyone with a prescription for dapagliflozin |
| Cost to patient | As low as $0, up to $175 savings per 30-day fill | $0 for those still enrolled through Dec 31, 2026 | Typically $290–$405 with a discount card; lower than brand cash price |
| Medicare/Medicaid eligible? | No | Previously yes, case-by-case | Yes, if your Part D or Medicaid formulary covers the generic |
| Income requirement | None | Previously ≤300% FPL for this drug category | None |
The practical shift: Before May 2026, the path for an uninsured patient was "apply to AZ&Me and get brand Farxiga free." Now, for a new patient, the realistic path is "ask your prescriber about generic dapagliflozin, then use a pharmacy discount card to get the generic price down further." That's a real change in the cost math, not just a paperwork inconvenience.
If You're Already Enrolled in AZ&Me
Confirm your enrollment end date
Your assistance runs through December 31, 2026. Mark that date now rather than discovering it at the pharmacy counter in January 2027.
Talk to your prescriber about generic dapagliflozin before your enrollment ends
Switching before the cutoff, rather than after, avoids a gap month where you have neither active AZ&Me coverage nor an established generic prescription and pharmacy routine.
Check your specific insurance status for 2027
If your insurance situation has changed since you first enrolled, re-verify what coverage — commercial, Medicare, Medicaid, or none — you'll actually have once AZ&Me ends, since that determines which of the remaining options applies to you.
If You're New to Farxiga in 2026
Ask directly whether generic dapagliflozin fits your case
Generic dapagliflozin covers the same core FDA-approved uses as brand Farxiga for many patients. Ask your prescriber whether there's a clinical reason you specifically need the brand, since for most patients there isn't one.
If you have commercial insurance, use the Farxiga Savings Card only if you're prescribed the brand
The savings card applies to brand Farxiga specifically. If your plan already covers generic dapagliflozin at a lower copay, the card may not be relevant to your situation at all.
If you're uninsured, price-compare generic dapagliflozin across pharmacies
Cash prices for the generic have varied meaningfully by pharmacy and by discount card. Comparing a couple of nearby pharmacies plus a free discount card app before filling can meaningfully change your monthly cost.
If cost is still unmanageable, look at independent copay foundations
Nonprofit foundations that operate separately from AstraZeneca sometimes fund diabetes, heart failure or kidney disease medications and aren't affected by AZ&Me's Farxiga-specific closure.
Medicare and Medicaid Patients
Medicare and Medicaid patients were never eligible for the Farxiga Savings Card, and the AZ&Me closure removes what had been one of the only manufacturer-side options for this specific brand-name drug.
| Coverage | Brand Farxiga | Generic Dapagliflozin |
|---|---|---|
| Medicare Part D | Usually covered, often with prior authorization; tier and copay vary by plan | Frequently covered at a lower tier once available on the formulary |
| Medicaid | Varies by state formulary | Generally preferred over brand where available |
| Farxiga Savings Card | Not eligible | Not applicable — card is brand-specific |
For low-income Medicare patients: If your Part D copay for either brand or generic dapagliflozin is still unaffordable, ask about Extra Help (the Low-Income Subsidy) through the Social Security Administration before assuming there's no assistance available at all.
Decision Tree: What's Your Move?
Were you enrolled in AZ&Me for Farxiga before May 1, 2026?
This single date determines your path
Coverage continues to Dec 31, 2026
Use this time to plan your next step
Switch to generic before the cutoff
Avoid a coverage gap in January
Have commercial insurance?
Determines whether savings card applies
Ask about generic dapagliflozin first
Then layer a savings card or discount program on top
Still unaffordable?
Independent copay foundations are your remaining option
Step-by-Step: Switching to Generic Dapagliflozin
Bring it up at your next appointment, or call in between
Ask specifically: "Is there a clinical reason I need brand Farxiga instead of generic dapagliflozin?" For most patients, the answer is no, and the switch is straightforward.
Confirm your pharmacy has the generic in stock
Generic availability expanded through 2026 but supply has varied by pharmacy and region during the rollout. Call ahead before showing up expecting an immediate fill.
Compare cash price with a discount card even if you have insurance
Occasionally a discount card's generic price beats your plan's copay, particularly on high-deductible plans early in the year. It costs nothing to compare both at the counter.
Watch your first few fills for any difference in effect
Generic dapagliflozin uses the same active ingredient as brand Farxiga. If you notice any unexpected changes after switching, that's worth a call to your prescriber, though it isn't expected with a straightforward generic substitution.
What to Do If You're Denied or Priced Out
1. Don't assume "no PAP" means "no help." The manufacturer program closing to new Farxiga patients doesn't eliminate every assistance option — it removes one specific one.
2. Check independent copay and disease-specific foundations. Organizations such as the PAN Foundation, the HealthWell Foundation and NeedyMeds operate separately from AstraZeneca and periodically fund diabetes, heart failure and chronic kidney disease medications.
3. Ask your pharmacist about the lowest verified cash price nearby. Generic pricing has varied enough between pharmacies that a quick call-around can be worth real money.
4. Revisit Extra Help if you're on Medicare. Low-income Medicare beneficiaries who haven't applied for the Part D Low-Income Subsidy may be leaving real savings on the table on both brand and generic dapagliflozin copays.
Frequently Asked Questions
No. AstraZeneca's AZ&Me program stopped accepting new Farxiga and Xigduo XR applicants as of May 1, 2026, because generic dapagliflozin became broadly available.
Patients who were already enrolled before May 1, 2026 continue receiving assistance through December 31, 2026, after which the program ends for this medication.
AstraZeneca cited the broad availability of generic dapagliflozin as the reason, since patient assistance programs are generally intended for brand-name drugs without an affordable generic alternative.
No. The Farxiga Savings Card is only available to commercially insured or cash-paying patients. Medicare, Medicaid, TRICARE and other government-funded insurance make you ineligible for the manufacturer copay card.
Ask your prescriber about switching to generic dapagliflozin, compare pharmacy discount card pricing, and look into independent copay foundations, since the manufacturer PAP is no longer accepting new Farxiga applicants.
Generic dapagliflozin contains the same active ingredient and is held to the same FDA bioequivalence standards as the brand version. Ask your prescriber if you have questions specific to your situation.
This specific closure applies to Farxiga and Xigduo XR. AstraZeneca has made separate, unrelated changes to other products in its portfolio at different times, so check the current AZ&Me program page for the status of any other medication.
Cash prices have varied, generally running somewhat below brand Farxiga's cash price and further reduced with a pharmacy discount card. Prices vary by pharmacy and region, so comparing a few options is worth the extra few minutes.
Not automatically. Prior authorizations are often tied to the specific drug and NDC submitted. Ask your pharmacy or insurer whether a new authorization is needed when switching from brand to generic.
No. This is a program-wide policy change affecting all new Farxiga applicants, not an individual eligibility denial, so there isn't an appeal process that reopens enrollment for this specific medication.
How We Researched This Guide
References
- AZ&Me — Important Program Updates (Farxiga/Xigduo XR closure notice)
- Farxiga.com — Savings and Insurance Support
- Social Security Administration — Extra Help with Medicare Prescription Drug Costs
- NeedyMeds — independent patient assistance directory
- HealthWell Foundation — independent copay assistance
- Patient Access Network (PAN) Foundation
Related Resources
- Patient Assistance Program Income Limits: 2026 Comparison
- What Is a Copay Accumulator?
- Jardiance Patient Assistance Program
- NovoCare vs Lilly Cares: Patient Assistance Compared
- How to Appeal a Prescription Denial
Editorial Policy: Refill Relay medical content is researched using manufacturer program pages and current pricing/availability reporting. Because this program's status changed mid-year and generic rollout and pricing continue to shift through 2026, always confirm current availability directly with AstraZeneca, your pharmacy, or your prescriber before making a decision.